Therapeutic Response

CD117 + status confers therapeutic sensitivity to Imatinib in patients with Gastrointestinal Stromal Tumor.

Statements

Source and description
Gleevec (imatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to imatinib for the treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).
Glivec (imatinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).
Glivec (imatinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized imatinib for the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD 117) positive gastrointestinal stromal tumors (GIST). Patients who have a low or very low risk of recurrence should not received adjuvant treatment.
Imatinib Therapy - GIST. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved imatinib for reimbursement as a treatment option for the treatment of adult patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).
Imatinib Therapy - GIST. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved imatinib for reimbursement as a treatment option for the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive gastrointestinal stromal tumors (GIST).